Brokers Offer Predictions for Pyxis Oncology FY2024 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Pyxis Oncology in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.00) for the year, down from their prior estimate of ($0.89). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.44) EPS and FY2028 earnings at ($0.75) EPS.

PYXS has been the topic of a number of other reports. Royal Bank of Canada restated an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Thursday, September 19th. Stifel Nicolaus assumed coverage on Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Stephens started coverage on Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $9.57.

Pyxis Oncology Trading Down 2.1 %

Shares of Pyxis Oncology stock opened at $4.19 on Friday. The firm has a market cap of $249.16 million, a PE ratio of -4.07 and a beta of 1.27. The stock has a 50 day moving average of $3.69 and a 200 day moving average of $3.65. Pyxis Oncology has a 12 month low of $1.35 and a 12 month high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC increased its holdings in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after buying an additional 5,484 shares in the last quarter. Pier 88 Investment Partners LLC raised its holdings in Pyxis Oncology by 7.0% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 121,610 shares of the company’s stock worth $446,000 after purchasing an additional 7,910 shares during the period. Fullcircle Wealth LLC acquired a new stake in Pyxis Oncology in the second quarter valued at approximately $40,000. SG Americas Securities LLC acquired a new position in shares of Pyxis Oncology during the 1st quarter worth approximately $59,000. Finally, Jane Street Group LLC increased its stake in shares of Pyxis Oncology by 40.8% during the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after purchasing an additional 14,349 shares in the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.